These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

880 related items for PubMed ID: 15886476

  • 1. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G, Briasoulis E, Karavassilis V, Mauri D, Tzamakou E, Rammou D, Pavlidis N.
    Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL.
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [Abstract] [Full Text] [Related]

  • 3. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 4. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
    Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ.
    J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
    [Abstract] [Full Text] [Related]

  • 5. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA, Hoffman PC, Drinkard LC, Watson S, Samuels BL, Golomb HM, Vokes EE.
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [Abstract] [Full Text] [Related]

  • 6. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA, Wang H, Hamilton J, Delgrosso A, Zhang R, Freda T, Zamboni WC.
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [Abstract] [Full Text] [Related]

  • 7. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 Aug; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 8. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [Abstract] [Full Text] [Related]

  • 9. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, Yim A, Chan AT, Yeo W, Chak K, Johnson P.
    Cancer; 2002 Oct 01; 95(7):1511-9. PubMed ID: 12237920
    [Abstract] [Full Text] [Related]

  • 10. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study.
    Stathopoulos GP, Rigatos SK, Christodoulou C, Malamos NA, Deliyiannis F, Stathopoulos JG, Skarlos DV.
    Cancer Chemother Pharmacol; 2004 Sep 01; 54(3):259-64. PubMed ID: 15127231
    [Abstract] [Full Text] [Related]

  • 11. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
    Tolcher AW, O'Shaughnessy JA, Weiss RB, Zujewski J, Myhand RC, Schneider E, Hakim F, Gress R, Goldspiel B, Noone MH, Brewster LR, Gossard MR, Cowan KH.
    Clin Cancer Res; 1997 May 01; 3(5):755-60. PubMed ID: 9815746
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH, Zamboni WC, Tait NS, Meisenberg BR, Doyle LA, Edelman MJ, Hausner PF, Egorin MJ, Van Echo DA.
    Cancer Chemother Pharmacol; 2000 May 01; 46(6):442-8. PubMed ID: 11138457
    [Abstract] [Full Text] [Related]

  • 13. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE, Haraf DJ, Drinkard LC, Hoffman PC, Ferguson MK, Vogelzang NJ, Watson S, Lane NJ, Golomb HM.
    Cancer Chemother Pharmacol; 1995 May 01; 35(4):304-12. PubMed ID: 7530173
    [Abstract] [Full Text] [Related]

  • 14. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP.
    Clin Cancer Res; 2002 Mar 01; 8(3):691-7. PubMed ID: 11895897
    [Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
    Herben VM, Panday VR, Richel DJ, Schellens JH, van der Vange N, Rosing H, Beusenberg FD, Hearn S, Doyle E, Beijnen JH, ten Bokkel Huinink WW.
    J Clin Oncol; 1999 Mar 01; 17(3):747-55. PubMed ID: 10071262
    [Abstract] [Full Text] [Related]

  • 16. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT.
    Cancer; 1999 Dec 01; 86(11):2291-300. PubMed ID: 10590370
    [Abstract] [Full Text] [Related]

  • 17. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
    Gordon AN, Hancock KC, Matthews CM, Messing M, Stringer CA, Doherty MG, Teneriello M.
    Gynecol Oncol; 2002 Apr 01; 85(1):129-35. PubMed ID: 11925132
    [Abstract] [Full Text] [Related]

  • 18. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
    Bunn PA, Kelly K.
    Semin Oncol; 1997 Aug 01; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
    [Abstract] [Full Text] [Related]

  • 19. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
    Brown JV, Peters WA, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP.
    Gynecol Oncol; 2000 Dec 01; 79(3):495-8. PubMed ID: 11104627
    [Abstract] [Full Text] [Related]

  • 20. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R, Hornedo J, Colomer R, Mendiola C, Brandariz A, Sevilla E, Alvarez-Vicent J, Cortés-Funes H.
    Semin Oncol; 1995 Dec 01; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.